%0 Journal Article %1 Mouawad.2009 %A Mouawad, R. %A Spano, J. P. %A Comperat, E. %A Capron, F. %A Khayat, D. %D 2009 %J Eur.J.Cancer %K Assay C Endothelial Enzyme-Linked Factor France Growth Immunosorbent Laboratories Medical Oncology Prognosis Research Vascular cells %N 8 %P 1407-1414 %T Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome %U PM:19157860 %V 45 %X PURPOSE: The presence of metastases in regional lymph nodes is a strong indicator of poor patient survival in many types of cancer. It has recently been shown that vascular endothelial growth factor-C (VEGF-C), and its receptor VEGFR-3, may play a pivotal role in the promotion of metastasis to regional lymph nodes. This study was designed to detect and evaluate whether the expression of VEGFR-3 or its soluble form plays a role in metastatic malignant melanoma and to determine the relationship with clinicopathological parameters and patients outcome. EXPERIMENTAL DESIGN: VEGFR-3 expression on melanoma tumour was evaluated by immunohistochemical study. Using a sensitive enzyme-linked immunosorbent assay, sVEGFR-3 was measured in sera of 60 metastatic melanoma patients in comparison with 30 healthy controls. RESULTS: Immunohistochemical study demonstrated a high expression of VEGFR-3 in melanoma cells. Median level of pre-treatment sVEGFR-3 was significantly higher (p=0.00001) in melanoma

@article{Mouawad.2009, abstract = {PURPOSE: The presence of metastases in regional lymph nodes is a strong indicator of poor patient survival in many types of cancer. It has recently been shown that vascular endothelial growth factor-C (VEGF-C), and its receptor VEGFR-3, may play a pivotal role in the promotion of metastasis to regional lymph nodes. This study was designed to detect and evaluate whether the expression of VEGFR-3 or its soluble form plays a role in metastatic malignant melanoma and to determine the relationship with clinicopathological parameters and patients outcome. EXPERIMENTAL DESIGN: VEGFR-3 expression on melanoma tumour was evaluated by immunohistochemical study. Using a sensitive enzyme-linked immunosorbent assay, sVEGFR-3 was measured in sera of 60 metastatic melanoma patients in comparison with 30 healthy controls. RESULTS: Immunohistochemical study demonstrated a high expression of VEGFR-3 in melanoma cells. Median level of pre-treatment sVEGFR-3 was significantly higher (p=0.00001) in melanoma}, added-at = {2010-02-05T11:28:39.000+0100}, author = {Mouawad, R. and Spano, J. P. and Comperat, E. and Capron, F. and Khayat, D.}, biburl = {https://www.bibsonomy.org/bibtex/2f884e45818fceca6752fd842542c8094/kanefendt}, interhash = {9973c74f2a6c0fffb54c299f689f3472}, intrahash = {f884e45818fceca6752fd842542c8094}, journal = {Eur.J.Cancer}, keywords = {Assay C Endothelial Enzyme-Linked Factor France Growth Immunosorbent Laboratories Medical Oncology Prognosis Research Vascular cells}, number = 8, pages = {1407-1414}, timestamp = {2010-02-05T11:28:51.000+0100}, title = {Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome}, url = {PM:19157860}, volume = 45, year = 2009 }